Synlett 2019; 30(19): 2148-2152
DOI: 10.1055/s-0039-1690724
letter
© Georg Thieme Verlag Stuttgart · New York

Acetic Acid Catalysed One-Pot Synthesis of Pyrrolo[1,2-a]quinoxaline Derivatives

Pia N. M. Allan
,
Martyna I. Ostrowska
,
Bhaven Patel
We thank London Metropolitan University for funding.
Further Information

Publication History

Received: 11 September 2019

Accepted after revision: 07 October 2019

Publication Date:
22 October 2019 (online)


Abstract

An efficient acetic acid catalysed reaction has been developed for the synthesis of 4-aryl substituted pyrrolo[1,2-a]quinoxalines from readily available starting materials. A range of structures have been synthesised in very good to excellent yields. The one-pot reaction proceeds through imine formation, cyclisation followed by air oxidation.

Supporting Information

 
  • References and Notes

    • 3a Guillon J, Cohen A, Gueddouda NM, Das RN, Moreau S, Ronga L, Savrimoutou S, Basmaciyan L, Monnier A, Monget M, Rubio S, Garnerin T, Azas N, Mergny J.-L, Mullie C, Sonnet P. J. Enzyme Inhib. Med. Chem. 2017; 32: 547
    • 3b Ronga L, Del Favero M, Cohen A, Soum C, Le Pape P, Savrimoutou S, Pinaud N, Mullie C, Daulouede S, Vincendeau P, Farvacques N, Agnamey P, Pagniez F, Hutter S, Azas N, Sonnet P, Guillon J. Eur. J. Med. Chem. 2014; 81: 378
    • 3c Guillon J, Mouray E, Moreau S, Mullie C, Forfar I, Desplat V, Belisle-Fabre S, Pinaud N, Ravanello F, Le-Naour A, Leger JM, Gosmann G, Jarry C, Deleris G, Sonnet P, Grellier P. Eur. J. Med. Chem. 2011; 46: 2310
    • 4a Desplat V, Moreau S, Gay A, Fabre SB, Thiolat D, Massip S, Macky G, Godde F, Mossalayi D, Jarry C, Guillon J. J. Enzyme Inhib. Med. Chem. 2010; 25: 204
    • 4b Desplat V, Moreau S, Belisle-Fabre S, Thiolat D, Uranga J, Lucas R, de Moor L, Massip S, Jarry C, Mossalayi DM, Sonnet P, Déléris G, Guillon J. J. Enzyme Inhib. Med. Chem. 2011; 26: 657
  • 5 Guillon J, Borgne ML, Rimbault C, Moreau S, Savrimoutou S, Pinaud N, Baratin S, Marchivie M, Roche S, Bollacke A, Pecci A, Alvarez L, Desplat V, Jose J. Eur. J. Med. Chem. 2013; 65: 205
  • 6 Guillon J, Dallemagne P, Pfeiffer B, Renard P, Manechez D, Kervran A, Rault S. Eur. J. Med. Chem. 1998; 33: 293
  • 7 Campiani G, Morelli E, Gemma S, Nacci V, Butini S, Hamon M, Novellino E, Greco G, Cagnotto A, Goegan M, Cervo L, Valle FD, Fracasso C, Caccia S, Mennini T. J. Med. Chem. 1999; 42: 4362
    • 8a Jacobsen EJ, Stelzer LS, Belonga KL, Carter DB, Im WB, Sethy VH, Tang AH, Von Voigtlander PF, Petke JD. J. Med. Chem. 1996; 39: 3820
    • 8b Colotta V, Cecchi L, Catarzi D, Filacchioini G, Martini C, Tacchi P, Lucacchini A. Eur. J. Med. Chem. 1995; 30: 133
  • 9 Gemma S, Colombo L, Forloni G, Savini L, Fracasso C, Caccia S, Salmona M, Brindisi M, Joshi BP, Tripaldi P, Giorgi G, Taglialatela-Scafati O, Novellino E, Fiorini I, Campiani G, Butini S. Org. Biomol. Chem. 2011; 9: 5137
  • 11 Kalinin AA, Islamova LN, Fazleeva GM. Chem. Heterocycl. Compd. 2019; 55: 584 ; and references therein
  • 12 Pereira MF, Thiéry V. Org. Lett. 2012; 14: 4754
  • 13 Sun Q, Liu L, Yang Y, Zha Z, Wang Z. Chin. Chem. Lett. 2019; 30: 1379
    • 16a Guillon J, Forfar I, Mamani-Matsuda M, Desplat V, Saliege M, Thiolat D, Massip S, Tabourier A, Léger J. -M, Dufaure B. Bioorg. Med. Chem. 2007; 15: 194
    • 16b Cheeseman GW. H, Tuck B. J. Chem. Soc. (C) 1966; 852
  • 18 Verma AK, Jha RR, Kasi Sankar V, Aggarwal T, Singh R, Chandra R. Eur. J. Org. Chem. 2011; 6998
  • 19 Huo H.-R, Tang X.-Y, Gong Y.-F. Synthesis 2018; 50: 2727
  • 20 Krishna T, Reddy TR, Laxminarayana E, Kalita D. ChemistrySelect 2019; 4: 250
  • 22 Typical Procedure for the Synthesis of Pyrrolo[1,2-a]quinoxaline 3a: To a solution of 2-(1H-pyrrol-1-yl)aniline (1 equiv) in methanol (5 mL) were added benzaldehyde (1 equiv) and acetic acid (0.1 equiv) and the mixture was heated to 60 °C for 8 h. The reaction mixture was allowed to cool to room temperature and the solvent was removed under reduced pressure. The crude reaction mixture was purified by column chromatography to give 2-substituted pyrrolo[1,2-a]quinoxaline 3a as a pale-yellow solid; mp 118–120 °C. IR (neat): 2929 (CH) cm–1. 1H NMR (500 MHz, CDCl3): δ = 8.07 (dd, J = 7.7, 1.4 Hz, 1 H, ArH), 7.99–8.04 (m, 5 H, 5 × ArH), 7.88 (dd, J = 8.0, 1.4 Hz, 1 H, ArH), 7.01 (dd, J = 3.8, 1.3 Hz, 1 H, ArH), 6.90 (dd, J = 3.9, 2.7 Hz, 1 H, ArH). 13C (126 MHz, CDCl3): δ = 154.4 (C), 138.4 (C), 136.2 (C), 130.2 (CH), 129.7 (CH), 128.6 (2 × CH), 128.5 (2 × CH), 127.4 (CH), 127.1 (C), 125.3 (C), 125.2 (CH), 114.5 (CH), 113.9 (CH), 113.6 (CH), 108.7 (CH). MS: m/z (%) = 244 (100) [M + H]+.
  • 23 Woon KL, Ariffin A, Ho KW, Chen S.-A. RSC Adv. 2018; 8: 9850